Group B Streptococcal Serine-Rich Repeat Proteins Promote Interaction With Fibrinogen and Vaginal Colonization

Nai-Yu Wang,1 Kathryn A. Patras,1 Ho Seong Seo,2,3 Courtney K. Cavaco,1 Berenice Rösler,1 Melody N. Neely,4 Paul M. Sullam,2 and Kelly S. Doran1,5

1Department of Biology and Center for Microbial Sciences, San Diego State University; 2Division of Infectious Diseases, Veteran Affairs Medical Center and the University of California San Francisco, California; 3Radiation Biotechnology Research Division, Advanced Radiation Technology Institute, Republic of Korea; 4Department of Immunology and Microbiology, School of Medicine, Wayne State University, Detroit, Michigan; and 5Department of Pediatrics, University of California San Diego School of Medicine, La Jolla

Group B streptococcus (GBS) can cause severe disease in susceptible hosts, including newborns, pregnant women, and the elderly. GBS serine-rich repeat (Srr) surface glycoproteins are important adhesins/invasins in multiple host tissues, including the vagina. However, exact molecular mechanisms contributing to their importance in colonization are unknown. We have recently determined that Srr proteins contain a fibrinogen-binding region (BR) and hypothesize that Srr-mediated fibrinogen binding may contribute to GBS cervicovaginal colonization. In this study, we observed that fibrinogen enhanced wild-type GBS attachment to cervical and vaginal epithelium, and that this was dependent on Srr1. Moreover, purified Srr1-BR peptide bound directly to host cells, and peptide administration in vivo reduced GBS recovery from the vaginal tract. Furthermore, a GBS mutant strain lacking only the Srr1 "latching" domain exhibited decreased adherence in vitro and decreased persistence in a mouse model of GBS vaginal colonization, suggesting the importance of Srr–fibrinogen interactions in the female reproductive tract.

Keywords. fibrinogen; GBS; Srr1; vaginal colonization.

Streptococcus agalactiae, or Group B streptococcus (GBS), is a Gram-positive bacterium frequently isolated from the gastrointestinal tract of healthy adults [1], which likely fosters GBS vaginal colonization [2]. Yet during pregnancy, GBS can disseminate to the fetus by crossing placental barriers to cause chorioamnionitis, funisitis, and pneumonitis [3], or can spread to the newborn during vaginal birth through aspiration of infected fluids [4]. Consequently, GBS is currently a leading cause of neonatal infectious morbidity and mortality, annually impacting over 2000 live births in the United States [5, 6]. Additionally, although mucosal colonization rates are similar between elderly populations and younger individuals, elderly adults account for >40% of GBS invasive disease and >50% of GBS-related deaths [7]. Initial exposure to GBS begins with asymptomatic colonization of mucosal tissues such as the vaginal tract. To persist in the vagina, a volatile environment constantly modulated by factors including commensal flora, pH, and steroid hormones, GBS must elaborate determinants that adhere to host cells and extracellular proteins. However, little is known about elements that promote GBS persistence in the female reproductive tract.

GBS surface-associated organelles, such as pilus tip adhesin (PilA) and serine-rich repeat (Srr) proteins, can instigate initial contact with host epithelium and promote cervical and vaginal attachment [8]. Srr glycoproteins are a large family of surface organelles found in numerous Gram-positive organisms that contribute to host-cell adhesion in various model systems [9–11].
Based on structural modeling, Srr proteins possess several conserved domains, including a specialized signal sequence, 2 extensive glycosylated Srr regions, and an LPXTG cell wall anchoring motif [12]. In GBS, there are 2 recognized srr gene alleles (srr1 and srr2) that are architecturally similar, but share <20% identity [13]. Thus far, Srr1 appears highly conserved (>85% nucleotide identity) and is found in the majority of GBS clinical isolates, including serotypes Ia, III, and V, while Srr2 is currently restricted to serotype III, multilocus sequencing type (ST)–17 strains [13, 14]. These alleles likely both play important roles in host–pathogen contact, since epidemiological surveillance of maternal GBS isolates has determined that serotypes Ia, Ib, II, III, and V are readily isolated from cervicovaginal tract and account for 96% of neonatal cases [15]. GBS Srr-deficient strains exhibit reduced persistence in murine vaginal colonization [8] and are impaired in the development of septis [13] and meningitis [14]. However, the overall contribution of Srr proteins, and governing molecular mechanisms, to GBS colonization and pathogenesis has not fully been recognized.

We recently identified that Srr1 and Srr2 both contain a fibrinogen-binding domain that secures fibrinogen through a “dock, lock, and latch” (DLL) mechanism, similar to staphylococal adhesins SdrG and ClfA [16, 17]. The Srr binding region (Srr-BR) performs an analogous function to fibrinogen binding to staphylococcal adhesins SdrG and ClfA [16, 17]. Therefore, we hypothesize that the DLL mechanism of Srr proteins establishes and stabilizes fibrinogen binding to aid GBS interaction with reproductive tract epithelium and prolong GBS colonization.

**MATERIALS AND METHODS**

**Bacterial Strains**

*S. agalactiae* (GBS) wild-type (WT) clinical isolates used in this study, all originally isolated from human blood or cerebral spinal fluid, were NCTC 10/84 (serotype V) [19], COH1 (serotype III) [20], H36B (serotype Ib) [21], 515 (serotype Ia) [22], and A909 (serotype Ia) [23]. All isogenic srr mutants have been described previously [8, 14]. Briefly, the NCTC 10/84 Δsrr1 strain was constructed by allelic exchange mutagenesis (as described in [24]) where polymerase chain reaction (PCR) was used to generate an in-frame substitution of srr with the chloramphenicol acetyltransferase (*cat*) gene [14]. Additional srr1/2 mutants in COH1, H36B, 515, and A909 were generated by gene disruption using plasmid insertional mutagenesis as described elsewhere [25]. The isogenic variant of NCTC 10/84 in which the latch-like domain of the Srr1 binding region (BR) has been deleted, NCTC 10/84 Δlatch, has also been described previously [16]. GBS isolates from vaginal tracts of pregnant women were obtained from the Detroit Medical Center, Detroit, Michigan. GBS isolates were confirmed by Gram stain, colony morphology, ability to grow as pink colonies on CHROMagar StrepB (DRG International), and rapid agglutination using StrepTect Latex Group B test (Remel). GBS strains were grown in Todd–Hewitt Broth (THB) at 37°C. THB was supplemented with chloramphenicol (2 µg/mL) for Δsrr mutants, and erythromycin (5 µg/mL) for Δlatch.

**PCR to Determine srr Alleles**

Genomic DNA was isolated from A909 (srr1-positive control), COH1 (srr2-positive control), and clinical vaginal isolates using a standard phenol:chloroform extraction and ethanol precipitation. PCR was performed with primers (Srr1 forward, 5′AGTGTCGATACTGAAATGTTAGG TA3′ and Srr1 reverse, 5′TGGGTCAGAGAGCCCTGTA3′; Srr2 forward, 5′TCACCGAAATTTGGGTTTTAA3′ and Srr2 reverse, 5′AGGTTTAGTGAGCCTCAA3′) to amplify srr1 and srr2 genes. Allele status was determined by visualization of products using gel electrophoresis.

**Cell Lines**

Immortalized human vaginal (VK2/E6E7), ectocervical (Ect1/E6E7), and endocervical (End1/E6E7) epithelial cell lines were obtained from American Type Culture Collection (ATCC CRL-2616, ATCC CRL-2614, and ATCC CRL-2615, respectively) [26]. Cell lines (passage 5–20) were maintained in keratinocyte serum-free medium (KSF) with 0.5 ng/mL human recombinant epidermal growth factor and 0.05 mg/mL bovine pituitary extract at 37°C with 5% CO₂.

**In Vitro Adherence Assays**

Cells were grown to confluency (monolayer) in 24-well plates, and incubated for 30 minutes with mid-log phase GBS at a multiplicity of infection (MOI) of 1. Cells were washed 6x with phosphate buffered saline (PBS), and 0.25% trypsin–ethylenediaminetetraacetic acid (EDTA) and 0.025% Triton X-100 added to lyse cells. Lysate was plated on THB agar to enumerate bacterial colony-forming units (CFUs). Total adherent CFU percentage was calculated as (recovered CFU/original inoculum CFU) × 100%. For exogenous fibrinogen assays, human fibrinogen (Haematologic Technologies) was either added to cells, or incubated with mid-log phase GBS for 30 minutes prior to infection. For inhibition assays, 10 µg/mL of rabbit anti-(h)-fibrinogen antibody (Aniara) was added to media 30 minutes before performing adherence assays.
GBS Adherence to Immobilized Fibrinogen

Purified fibrinogen (0.4 μM) was immobilized on 96-well microtiter plates, incubated overnight at 4°C, and washed 3x with PBS. Overnight GBS cultures were adjusted to 10^6 CFU/mL in PBS, and 100 μL incubated on fibrinogen-coated plates for 30 minutes at 37°C. Wells were washed with PBS, and attached bacteria released with 100 μL of 0.25% trypsin-EDTA for 10 minutes at 37°C, and quantified on THB agar.

Light Microscopy

 Cells were cultured on glass coverslips to confluence. After an adherence assay (MOI of 100), cells were washed 6x with PBS. Coverslips were air-dried, heat-adherence assay (MOI of 100), cells were washed 6x with PBS. Overnight GBS cultures were adjusted to 10^6 CFU/mL in PBS, and 100 μL incubated on fibrinogen-coated plates for 30 minutes at 37°C. Wells were washed with PBS, and attached bacteria released with 100 μL of 0.25% trypsin-EDTA for 10 minutes at 37°C, and quantified on THB agar.

Immunofluorescence Microscopy

Cells were propagated on glass coverslips to 70%–90% confluency. After mounting coverslips on slides using Vectashield with 4’,6-diamidino-2-phenylindole (DAPI; Vector Laboratories), proteins were detected under laser scanning microscope (Leica Microsystems). For protein binding assays, Srr1-BR and Srr1-BRΔlatch peptides were purified using methods described previously [16]. Cells were washed 3x with PBS and incubated in KSF with 50 μg/mL of protein for 1 hour at 37°C with 5% CO₂. Cells were fixed with 2% paraformaldehyde and incubated with primary antibody (mouse anti-FLAG antibody; 1:1000, Sigma Aldrich) at 4°C overnight. After washing, secondary antibody (Alexa Fluor 594-conjugated rabbit antimouse antibody; 1:1000, Life Technologies) was added for 1 hour. For endogenous fibrinogen detection, vaginal and cervical cells grown to approximately 90% confluency were fixed with 2% paraformaldehyde and primary (rabbit antihuman fibrinogen, CalBioChem) and secondary (Alexa Fluor 594-conjugated donkey antirabbit, Life Technologies) antibodies were applied to cells as described above.

Mouse Model of GBS Vaginal Colonization

All mouse work was approved by the Office of Lab Animal Care at San Diego State University and carried out using accepted veterinary standards. Eight- to twelve-week-old female CD1 mice (Charles River Laboratories) were injected intraperitoneally with 0.5 mg β-estradiol in 100 μL sesame oil on day -1 [8, 27]. On day 0, 1 hour prior to bacterial inoculation, 14–26 μg of Srr1-BR or Srr2-BR in a 10 μL suspension, or 10 μL of PBS, was administered into the vaginal lumen. All mice were vaginally inoculated with a 1:1 ratio of NCTC 10/84 and Δlatch (a total of 1 x 10^7 CFU suspended in 10 μL PBS). On successive days (days 1–5), vaginal lumens were swabbed as described above. The Δlatch mutant strain was distinguished from WT by plating on CHROMagar plates with 5 μg/mL erythromycin.

Statistical Analysis

GraphPad Prism version 5.04 was used for statistical analyses. Differences in recovered bacteria from in vitro assays were evaluated using Student t test. In vivo results for peptide treatment assays or competition experiments were analyzed by Mann–Whitney and repeated measures 2-way ANOVA, respectively. Statistical significance was accepted at P < .05.
Figure 1. GBS interaction with fibrinogen and contribution of Srr to reproductive tract adherence. A, GBS clinical isolates (n = 40) from vaginal tract of pregnant women and invasive isolates A909, 515, H36B, COH1, and NCTC 10/84 (n = 5) were incubated on 96-well microtiter plates coated with immobilized fibrinogen (0.4 µM). Srr allele status was determined by PCR as described in Materials and Methods. B, Representative GBS serotypes Ia, Ib, III, and V and isogenic Δsrr mutants were incubated with immobilized fibrinogen as in (A). Statistical comparisons were made between mutant and parental strains. C, Adherence of WT GBS and isogenic Δsrr mutants to hVECs at an MOI of 1. Total adherence values, percentage, of parental strains compared to original inoculum are indicated in parentheses. Statistical comparisons were made between mutant and parental strains. D–F, Adherence of WT NCTC 10/84 or isogenic Δsrr1 to hVEC, ecto-, or endocervical cells (MOI of 1) with or without blocking by antifibrinogen antibody (10 µg/mL). Values are expressed as the relative total of cell-associated CFUs recovered compared to original inoculum. Experiments were repeated at least twice with 4 replicates, and data from a representative experiment are shown. Data were analyzed by Student t test. *P < .05; **P < .005; ***P < .001. Abbreviations: CFUs, colony-forming units; CSF, cerebral spinal fluid; GBS, group B streptococcus; hVECs, human vaginal epithelial cells; MOI, multiplicity of infection; PCR, polymerase chain reaction; srr, serine-rich repeat gene; WT, wild type.

Figure 2. Srr-BR peptides compete with WT GBS to reduce vaginal bacterial load in vivo. Purified Srr1-BR (A) or Srr2-BR (B) was introduced to the murine vaginal lumen 1 hour before and 1 hour after inoculation with 1 × 10^7 CFUs of WT NCTC 10/84. Five hours postinoculation, vaginal tracts were swabbed, and recovered GBS quantified as described in Materials and Methods. Dots represent values for individual mice and lines represent median values. Experiments were conducted independently at least twice, and data from 1 representative experiment are shown. Data were analyzed by Mann–Whitney test. *P < .05. Abbreviations: BR, binding region; CFUs, colony-forming units; GBS, group B streptococcus; PBS, phosphate buffered saline; Srr, serine-rich repeat; WT, wild type.
Srr2-deficient GBS, (Figure 1D–F, Supplementary Figure 1A–C). This further validates that fibrinogen is a key mediator of GBS Srr-conferred attachment to host cells. We next examined whether this phenotype could be reproduced in vivo. We previously found that Δsrr1 displays reduced murine vaginal persistence over time [8]. To investigate the importance of Srr–fibrinogen interaction to initial GBS establishment within the vagina, we performed a competitive binding experiment by administering purified peptides of Srr1- or Srr2-binding regions (Srr1-BR, Srr2-BR) prior to and during vaginal inoculation with WT GBS. We detected a significant reduction of GBS load 5 hours postinoculation in mice treated with either Srr1-BR (Figure 2A) or Srr2-BR (Figure 2B) compared to PBS-treated controls. This reduction in bacterial load was still present 24 hours postinoculation (data not shown).

Our data suggest that Srr-mediated fibrinogen binding aids GBS in vaginal epithelial attachment early on during colonization, and supports our previous observation of reduced Δsrr1 vaginal persistence [8].

Fibrinogen Enhances GBS Attachment to Vaginal and Cervical Epithelial Cells

Fibrinogen is an abundant, soluble blood protein synthesized mainly by the liver, and although well known for its involvement in blood clotting, fibrinogen is also incorporated into extracellular matrix of multiple tissues [31]. Because we observed that GBS–fibrinogen interactions contribute to cervicovaginal adherence (Figure 1), we examined the hypothesis that fibrinogen enhances GBS–host cell attachment. Exogenous fibrinogen was added to GBS cultures prior to vaginal and cervical cell

Figure 3. Expression of fibrinogen and its contribution to Srr1-mediated GBS attachment to cervicovaginal epithelia in vitro. A, Adherence of WT NCTC 10/84 or isogenic Δsrr1 to epithelial cells (MOI of 1) with or without the addition of exogenous fibrinogen (20 µg/mL). Data were analyzed by Student t test. *P < .05; **P < .005; ***P < .001. B, Immunofluorescence staining of endogenous fibrinogen (red) on all 3 cell types, and nuclei were visualized with DAPI (blue). (Magnification = 630×, scale bar = 20 µm). Experiments were repeated at least twice with 4 replicates, and data from a representative experiment are shown. Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; GBS, group B streptococcus; MOI, multiplicity of infection; Srr, serine-rich repeat; srr, serine-rich repeat gene; WT, wild type.
inoculation, which significantly enhanced WT adherence to epithelium, but did not alter adherence of the Δsrr1 mutant (Figure 3A). Although the liver is the primary source of fibrinogen, extrahepatic synthesis has been described in mucosal epithelial cells from the cervix, intestine, and lung [32–34]. Additionally, fibrinogen has been identified in human vaginal lavage fluid [35, 36]. To confirm fibrinogen production in our immortalized cell lines, we performed immunofluorescent microscopy and detected fibrinogen in all 3 cell lines, although to a lesser extent in ectocervical epithelium (Figure 3B). Moreover, reverse-transcription PCR and Western blot analysis of cell lysates revealed that hVEC, ecto-, and endocervical cells produce fibrinogen (data not shown).

**Srr1 Latch Domain Promotes Fibrinogen Binding and Cervicovaginal Adherence**

In our collection of vaginal GBS isolates, we observed that the majority of vaginal isolates possessed srr1 (Figure 1A), and therefore examined the molecular mechanisms of Srr1 in greater detail. A 13-amino acid sequence (NISGDSDANAEIK) within the C-terminal domain of Srr1 fibrinogen-binding region of strain NCTC 10/84, designated the “latch” domain (Figure 4A), was recently identified and shown to mediate GBS-fibrinogen interaction, promoting the development of GBS meningitis [16]. To examine the role of the latch domain in GBS vaginal colonization, we measured adherence of a Δlatch mutant in vitro. GBS lacking the latch domain exhibited a significantly decreased ability to attach to vaginal and cervical cells compared to WT, although this phenotype was not as dramatic as the entire srr1 deletion (Figure 4A). Micrographs revealed fewer adherent Srr1 or Srr1-latch deficient GBS on vaginal cells compared to WT (Figure 4B).

We next sought to confirm the importance of Srr–latch–fibrinogen interactions to GBS-host adherence. The WT and Δlatch strains were cultured with exogenous fibrinogen, and then incubated with host-cell monolayers. As we observed previously, WT adherence to vaginal and cervical epithelium was enhanced by adding fibrinogen, while Δlatch binding was not affected (Figure 5A). These results indicate that the latch

---

**Figure 4.** Srr1 Latch domain contributes to GBS cervicovaginal adherence. A, Schematic diagram of the structure of Srr1 protein, including the latch domain. B, Adherence of WT NCTC 10/84, Δsrr1 or Δlatch to epithelial cell types (MOI of 1). Data were analyzed by Student t test. *P < .05; **P < .005; ***P < .001. C, Gram stain of human vaginal epithelial cells infected with WT NCTC 10/84, Δsrr1 or Δlatch at an MOI of 100 (magnification = 1000×). Experiments were repeated at least twice with 4 replicates, and data from a representative experiment are shown. Abbreviations: AA, amino acids; BR, binding region; GBS, group B streptococcus; LPxTG, cell wall anchoring motif; MOI, multiplicity of infection; Srr, serine-rich repeat; srr, serine-rich repeat gene; WT, wild type.
domain plays a crucial role in GBS interaction with fibrinogen, which in turn enhances host–bacteria association.

Because we observed here that the Srr-BR was sufficient to limit GBS colonization in vivo (Figure 2), we examined cellular binding of purified Srr1-BR and Srr1-BRΔlatch peptides. Vaginal and cervical cells were incubated with FLAG-tagged purified peptides (Srr1-BR and Srr1-BRΔlatch) probed with anti-FLAG antibody (red). Nuclei were visualized with DAPI (blue). (Magnification = 630×, scale bar = 20 µm.) Experiments were repeated at least twice with 4 replicates, and data from a representative experiment are shown. Abbreviations: BR, binding region; DAPI, 4',6-diamidino-2-phenylindole; GBS, group B streptococcus; MOI, multiplicity of infection; Srr, serine-rich repeat; WT, wild type.

**Figure 5.** Contribution of Srr1 latch domain to GBS–fibrinogen interaction cellular attachment. A. Adherence of WT NCTC 10/84 or isogenic Δlatch to epithelial cells (MOI of 1) with or without the addition of exogenous fibrinogen (20 µg/mL). Data were analyzed by Student t test. *P < .05; **P < .005. B. Immunofluorescence staining of epithelial cells incubated with FLAG-tagged purified peptides (Srr1-BR and Srr1-BRΔlatch) probed with anti-FLAG antibody (red). Nuclei were visualized with DAPI (blue). (Magnification = 630×, scale bar = 20 µm.) Experiments were repeated at least twice with 4 replicates, and data from a representative experiment are shown. Abbreviations: BR, binding region; DAPI, 4',6-diamidino-2-phenylindole; GBS, group B streptococcus; MOI, multiplicity of infection; Srr, serine-rich repeat; WT, wild type.

This same effect was observed in vaginal cells, but to a lesser extent (Figure 5B). These results provide additional evidence that interaction between GBS-Srr1 and multiple host-cell types is largely dependent on the presence of the latch domain.

**Srr1 Latch Domain Contributes to Vaginal Colonization In Vivo**

Our in vitro data indicated that Srr1 latch domain contributes to GBS cervical and vaginal adherence. To verify this contribution
in vivo, we utilized a mouse model of GBS vaginal colonization that has been described previously by our lab [8, 27]. Briefly, β-estradiol was first injected into the peritoneal cavity to synchronize estrus, and equal amounts of WT NCTC 10/84 and Δlatch (0.5 × 10^7 CFUs each) were introduced into the vaginal vault of mice (n = 11) in a competition assay. A, Persisting GBS were enumerated by plating on CHROMagar StrepB plates with and without 5 μg/mL erythromycin on successive days after infection. B, The ratio of WT GBS CFU to Δlatch CFUs over time. An overall ratio of 1 indicates equal numbers of WT and Δlatch CFUs. Dots represent values for individual mice and lines represent median values. Experiments were conducted independently at least twice, and data from 1 representative experiment are shown. Data were analyzed by repeated measures 2-way ANOVA. Abbreviations: CFUs, colony-forming units; GBS, group B streptococcus; Srr, serine-rich repeat; WT, wild type.

**Figure 6.** Contribution of Srr1 latch domain to GBS vaginal colonization in vivo. Equal amounts of WT NCTC 10/84 and Δlatch (0.5 × 10^7 CFUs each) were introduced into the vaginal vault of mice (n = 11) in a competition assay. A, Persisting GBS were enumerated by plating on CHROMagar StrepB plates with and without 5 μg/mL erythromycin on successive days after infection. B, The ratio of WT GBS CFU to Δlatch CFUs over time. An overall ratio of 1 indicates equal numbers of WT and Δlatch CFUs. Dots represent values for individual mice and lines represent median values. Experiments were conducted independently at least twice, and data from 1 representative experiment are shown. Data were analyzed by repeated measures 2-way ANOVA. Abbreviations: CFUs, colony-forming units; GBS, group B streptococcus; Srr, serine-rich repeat; WT, wild type.

GBS Srr1 Promotes Fibrinogen Interaction

**DISCUSSION**

Although GBS is an opportunistic microbe that rarely causes diseases in healthy individuals, it remains a significant neonatal pathogen despite prenatal screening and antibiotics prophylaxis. The female reproductive tract is a major reservoir for GBS, and GBS vaginal colonization has been reported in women from all ethnic backgrounds and stages of life [37–39]. Bacterial surface–associated organelles facilitate initial contact with host cells, and GBS Srr1 contributes to cervicovaginal attachment and vaginal persistence [8]; however, the precise mechanism of this host–pathogen interaction remains elusive. In this study, we focused on the contribution of Srr1 and its fibrinogen-binding capability to promote GBS cervicovaginal adherence and colonization.

Repetitive DNA sequences such as srr1 are common among microbial genomes and display size variability likely due to high recombination rates between repeats [40]. Intraspecies size divergence of srr1 appears in GBS isolates; however, the 5′ end (bp 1–1928) exhibits higher conservation in length [11], suggesting preserved function of the Srr1 5′ region across GBS strains. Human keratin 4 (K4) was previously determined to bind amino acids (aa) 485–642 of Srr1 promoting GBS adherence to laryngeal epithelium [11]. Our past results also indicated K4 contributes to Srr1-mediated GBS vaginal adherence; however, blocking with anti-K4 antibody only resulted in a 30% decrease in GBS adherence [8] compared to a ≥50% decrease in Δsrr1 adherence (Figure 1), suggesting other host factors also engage Srr1. We recently demonstrated that human fibrinogen is another Srr1 ligand, and interestingly, the fibrinogen-binding site is located between aa 303–641 [16], overlapping the K4-binding site. To confirm fibrinogen ligand specificity of the latch domain (aa 629–641) in Srr1-mediated GBS adherence, we compared WT and Δlatch attachment to vaginal epithelial cells pretreated with or without anti-K4 antibody. Our results show decreased Δlatch binding when cell-surface K4 is blocked (data not shown) suggesting that Srr1 latch domain absence does not affect GBS interaction with keratin 4. The fact that Srr proteins may interact with multiple host proteins, including K4, may explain why treatment with an anti-fibrinogen antibody did not always reduce WT adherence to the level observed with Srr-deficient GBS (Figure 1D-F, Supplementary Figure 1).

Fibrinogen synthesis is dramatically upregulated during inflammation or under stress exposure [41, 42], and blood fibrinogen levels increase 50% in pregnant women [43]. Based on this, and the presence of fibrinogen in vaginal lavage fluid [35, 36], it is highly likely that fibrinogen is available during GBS vaginal colonization. Our data indicate that 3 cell types from the female genital tract produce fibrinogen and immobilize fibrinogen on colonization in vivo and indicate that latch domain deficiency results in reduced fitness in the vaginal tract.
the cell surface. We have determined that vaginal cells express the fibrinogen-binding integrin αvβ1 (data not shown); however, further investigation to identify specific fibrinogen receptors on cervical and vaginal epithelial cells is still needed.

Although Δsrr1 mutants exhibit reduced adherence to immobilized fibrinogen compared to WT, its binding is still detectable. Likewise, Δsrr1 mutants still adhere to cervicovaginal epithelium, although to a lesser extent than WT, suggesting that additional bacterial factors promote this host–microbe interaction. Other GBS fibrinogen-binding proteins have been characterized, although specific binding sites and overall contribution to pathogenesis are not well understood. Multiple studies have established that GBS fibrinogen-binding protein from *S. agalactiae* (Fbs)–A and FbsB are important for cellular adherence or invasion [44–46], and recently, FbsA was suggested to have immunogenic potential [47]. Thus, it is likely that Srr is not the only factor interacting with fibrinogen during GBS vaginal colonization. Our data clearly establish that colonizing GBS isolates are capable of fibrinogen binding and genome sequence analysis is underway to completely profile fibrinogen-binding proteins. We have recently shown that Srr2 possesses a higher affinity for fibrinogen, and although Srr2-expressing strains are thought to be more virulent [13], it is currently unknown whether these 2 characteristics are directly related. Data presented here suggest that the binding region of both Srr1 and Srr2 can competitively inhibit GBS colonization in vivo; however, whether Srr2 is promotes GBS vaginal persistence during colonization remains to be determined.

In summary, our results demonstrate that fibrinogen plays an important role for Srr1-mediated GBS adherence within in the female reproductive tract, although the degree of fibrinogen binding varies across clinical isolates. This interaction is promoted by the 13-aa latch domain, which likely stabilizes fibrinogen binding via the DLL mechanism discovered previously. These findings, combined with further investigation of potential fibrinogen receptors on cervicovaginal epithelium, may provide novel targets for therapeutic development in preventing GBS vaginal colonization.

**Supplementary Data**

Supplementary materials are available at *The Journal of Infectious Diseases* online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**

**Acknowledgments.** We would like to thank the vivarium manager and staff at San Diego State University for support with animal husbandry. We are also grateful to Donna Runft and Lauryn Keefer for technical assistance with GBS vaginal isolates.

**Financial support.** This work was supported by grants from the California State University Program for Education and Research in Biotechnology (CSUPERB) and National Institutes of Health (NS051247 to K.S.D. and AI41513 and AI057433 to P.M.S.).

**Potential conflicts of interest.** All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**


